Site of Primary Tumor Has a Prognostic Role in Operable Breast Cancer: The International Breast Cancer Study Group Experience
Authors:
- Marco ColleoniMCMarco Colleoni
- David ZahriehDZDavid Zahrieh
- Richard D. GelberRGRichard D. Gelber
- Stig B. HolmbergSHStig B. Holmberg
- Jan E. MattssonJMJan E. Mattsson
- Carl-Magnus RudenstamCRCarl-Magnus Rudenstam
- Jurij LindtnerJLJurij Lindtner
- Darja ErženDEDarja Eržen
- Raymond SnyderRSRaymond Snyder
- John CollinsJCJohn Collins
- Martin F. FeyMFMartin F. Fey
- Beat ThürlimannBTBeat Thürlimann
- 1 March 2005
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (7) , 1390-1400
Abstract
Purpose: Cancer presenting at the medial site of the breast may have a worse prognosis compared with tumors located in external quadrants. For medial tumors, axillary lymph node staging may not accurately reflect the metastatic potential of the disease. Patients and Methods: Eight-thousand four-hundred twenty-two patients randomly assigned to International Breast Cancer Study Group clinical trials between 1978 and 1999 were classified as medial site (1,622; 19%) or lateral, central, and other sites (6,800; 81%). Median follow-up was 11 years. Results: A statistically significant difference was observed for patients with medial tumors versus those with nonmedial tumors in disease-free survival (DFS; 10-year DFS, 46% v 48%; HR, 1.10; 95% CI, 1.02 to 1.18; P = .01) and overall survival (10-year OS 59% v 61%; HR, 1.09; 1.01 to 1.19; P = .04). This difference increased after adjustment for other prognostic factors (HR, 1.22; 95% CI, 1.13 to 1.32 for DFS; and HR, 1.24; 95% CI, 1.14 to 1.35 for OS; both P = .0001). The risk of relapse for patients with medial presentation was largest for the node-negative cohort and for patients with tumors larger than 2 cm. In the subgroup of 2,931 patients with negative axillary lymph nodes, 10-year DFS was 61% v 67%, and OS was 73% v 80% for medial versus nonmedial sites, respectively (HR 1.33; 95% CI, 1.15 to 1.54; P = .0001 for DFS; and HR 1.40; 95% CI, 1.17 to 1.67; P = .0003 for OS). Conclusion: Tumor site has a significant prognostic utility, especially for axillary lymph node–negative disease, that should be considered in therapeutic algorithms. New staging procedures such as biopsy of the sentinel internal mammary nodes or novel imaging methods should be further studied in patients with medial tumors.Keywords
This publication has 26 references indexed in Scilit:
- Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast CancerJournal of Clinical Oncology, 2003
- Influence of tumor location on breast cancer prognosisInternational Journal of Cancer, 2003
- Endocrine Responsiveness and Tailoring Adjuvant Therapy for Postmenopausal Lymph Node-Negative Breast Cancer: A Randomized TrialJNCI: Journal of the National Cancer Institute, 2002
- Surgical Approach To Internal Mammary Lymph Node BiopsyJournal of the American College of Surgeons, 2001
- Radiotherapy and Chemotherapy in High-Risk Breast CancerNew England Journal of Medicine, 1998
- Effect of systemic adjuvant treatment on first sites of breast cancer relapseThe Lancet, 1994
- Prolonged Disease-Free Survival after One Course of Perioperative Adjuvant Chemotherapy for Node-Negative Breast CancerNew England Journal of Medicine, 1989
- Combination Adjuvant Chemotherapy for Node-Positive Breast CancerNew England Journal of Medicine, 1988
- Risk of Internal Mammary Lymph Node Metastases and Its Relevance on Prognosis of Breast Cancer PatientsAnnals of Surgery, 1983
- A new look at the statistical model identificationIEEE Transactions on Automatic Control, 1974